Cancer Research and Treatment

Original Articles

Breast cancer

Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade: Jeea Lee, Ga Yoon Ku, Haemin Lee, Hyung Seok Park, Ja Seung Ku, Jee Ye Kim, Seho Park, Byeong-Woo Park; Cancer Res Treat. 2022;54(4):1074-1080. Published online December 21, 2021; DOI: https://doi.org/10.4143/crt.2021.864

Purpose
There is a potential risk that lobular carcinoma in situ (LCIS) on preoperative biopsy might be diagnosed as ductal carcinoma in situ (DCIS) or invasive carcinoma in the final pathology. This study aimed to evaluate the rate of upgrade of LCIS on preoperative biopsy to DCIS or invasive carcinoma.
Materials and Methods
Data of 55 patients with LCIS on preoperative biopsy were analyzed. All patients underwent surgery between 1991 and 2016 at Severance Hospital in Seoul, Korea. We analyzed the rate of upgrade of preoperative LCIS to DCIS or invasive cancer in the final pathology. The clinicopathologic features related to the upgrade were evaluated.
Results
The rate of upgrade of LCIS to DCIS or invasive carcinoma was 16.4% (9/55). In multivariate analysis, microcalcification and progesterone receptor expression were significantly associated with the upgrade of LCIS (p=0.023 and p=0.044, respectively).
Conclusion
The current study showed a relatively high rate of upgrade of LCIS on preoperative biopsy to DCIS or invasive cancer. The presence of microcalcification and progesterone receptor expression may be potential predictors of upgradation of LCIS on preoperative biopsy. Surgical excision of the LCIS during preoperative biopsy could be a management option to identify the concealed malignancy.

Citations

Citations to this article as recorded by

Upgrade Rate and Long-term Outcomes of Lobular Neoplasia
Sara Ardila, Annabel Chen, Taylor Maramara, Danielle Henry, April Phantana-angkool
Current Breast Cancer Reports.2024; 16(1): 11. CrossRef
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants
Hannah L. Chung, Lavinia P. Middleton, Jia Sun, Gary J. Whitman
Breast Cancer Research and Treatment.2024; 205(3): 545. CrossRef
De-escalation of Surgical Intervention and Contemporary Management Recommendations for Lobular Neoplasia, Atypical Ductal Hyperplasia, and Ductal Carcinoma In Situ
Amanda L. Amin, Megan E. Miller
Current Breast Cancer Reports.2023; 15(3): 298. CrossRef
In Search of Calcifications : Histologic Analysis and Diagnostic Yield of Stereotactic Core Needle Breast Biopsies
Fazilet Yilmaz, Sean M Hacking, Linda Donegan, Lijuan Wang, Evgeny Yakirevich, Yihong Wang
American Journal of Clinical Pathology.2023; 160(2): 200. CrossRef

5,770 View
140 Download
4 Web of Science
4 Crossref

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study: Jiahui Huang, Xiaosong Chen, Xiaochun Fei, Ou Huang, Jiayi Wu, Li Zhu, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen; Cancer Res Treat. 2019;51(4):1336-1346. Published online February 12, 2019; DOI: https://doi.org/10.4143/crt.2018.504

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the changes of tumor infiltrating lymphocytes (TILs) between core needle biopsy (CNB) and surgery removed sample (SRS) in early stage breast cancer patients and to identify the correlating factors and prognostic significance of TILs changes.
Materials and Methods
A retrospective study was carried out on 255 patients who received CNB and underwent surgical resection for invasive breast cancer. Stromal TILs levels of CNB and SRS were evaluated respectively. Tumors with ≥50% stromal TILs were defined as lymphocyte-predominant breast cancer (LPBC). Clinicopathological variables were analyzed to determine whether there were factors associated with TILs changes. Log-rank tests and Cox proportional hazards models were used to analyze the influences of TILs and TILs changes on survival.
Results
SRS-TILs (median, 10.0%) were significant higher than CNB-TILs (median, 5.0%; p<0.001). Younger age (<60 years, p=0.016) and long surgery time interval (STI, ≥4 days; p=0.003) were independent factors correlating with higher TILs changes. CNB-LPBC patients showed better breast cancer-free interval (BCFI, p=0.021) than CNB-non-LPBC (CNB-nLPBC) patients. Patients were categorized into four groups according to the LPBC change pattern from CNB to SRS: LPBC→LPBC, LPBC→nLPBC, nLPBC→LPBC, and nLPBC→nLPBC, with estimated 5-year BCFI 100%, 100%, 69.7%, and 86.0% (p=0.016). nLPBC→LPBC pattern was an independent prognostic factor of worse BCFI (hazard ratio, 2.19; 95% confidence interval, 1.06 to 4.53; p=0.035) compared with other patterns.
Conclusion
TILs were significantly higher in SRS than in CNB. Higher TILs changes were associated with younger age and long STI. Changing from nLPBC to LPBC after CNB indicated a worse BCFI, which needs further validation.

Citations

Citations to this article as recorded by

A nomogram to predict the pathological complete response in patients with breast cancer based on the TILs-US score
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Koji Arihiro, Morihito Okada
Japanese Journal of Clinical Oncology.2024; 54(9): 967. CrossRef
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Anne Monette, Sarah Warren, J Carl Barrett, Charlie Garnett-Benson, Kurt A Schalper, Janis M Taube, Brian Topp, Alexandra Snyder
Journal for ImmunoTherapy of Cancer.2024; 12(7): e009427. CrossRef
Diagnostic performance of TILs–US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Erika Yokoyama, Makiko Tanaka, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Tetsuya Nakagiri, Koji Arihiro, Morihito Okada
International Journal of Clinical Oncology.2024; 29(12): 1860. CrossRef
Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer
Sean M. Hacking, Yihong Wang
Virchows Archiv.2023; 483(6): 765. CrossRef
Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer
Sean M. Hacking, Julie Karam, Kamaljeet Singh, Ece D. Gamsiz Uzun, Arlen Brickman, Evgeny Yakirevich, Ross Taliano, Yihong Wang
Pathology - Research and Practice.2023; 246: 154476. CrossRef
Tumor infiltrating lymphocytes and radiological picture of the tumor
Karolina Frankowska, Michał Zarobkiewicz, Izabela Dąbrowska, Agnieszka Bojarska-Junak
Medical Oncology.2023;[Epub] CrossRef
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma
Minna Mutka, Kristiina Joensuu, Marja Heiskala, Mine Eray, Päivi Heikkilä
Virchows Archiv.2023; 483(2): 215. CrossRef
Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
Yujie Lu, Yiwei Tong, Xiaochun Fei, Xiaosong Chen, Kunwei Shen
Cancer Medicine.2023; 12(15): 16264. CrossRef
Time interval between breast cancer diagnosis and surgery is associated with disease outcome
Siji Zhu, Shuai Li, Jiahui Huang, Xiaochun Fei, Kunwei Shen, Xiaosong Chen
Scientific Reports.2023;[Epub] CrossRef
Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer
Amalia H. Landén, Kian Chin, Anikó Kovács, Erik Holmberg, Eva Molnar, Axel Stenmark Tullberg, Fredrik Wärnberg, Per Karlsson
Acta Oncologica.2023; 62(12): 1862. CrossRef
Magnetic Resonance Imaging Features Associated with a High and Low Expression of Tumor-Infiltrating Lymphocytes: A Stratified Analysis According to Molecular Subtypes
Jiejie Zhou, Yi Jin, Haiwei Miao, Shanshan Lu, Xinmiao Liu, Yun He, Huiru Liu, Youfan Zhao, Yang Zhang, Yan-Lin Liu, Zhifang Pan, Jeon-Hor Chen, Meihao Wang, Min-Ying Su
Cancers.2023; 15(23): 5672. CrossRef
Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer
Giuseppe Angelico, Giuseppe Broggi, Rosario Caltabiano, Angela Santoro, Saveria Spadola, Nicoletta D’Alessandris, Giulia Scaglione, Michele Valente, Damiano Arciuolo, Alejandro Martin Sanchez, Gianluca Franceschini, Riccardo Masetti, Antonino Mulè, Gian F
Applied Sciences.2021; 11(15): 6788. CrossRef
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen K. van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm
npj Breast Cancer.2020;[Epub] CrossRef
Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?
Alexandra Caziuc, Diana Schlanger, Giorgiana Amarinei, George Calin Dindelegan
Journal of Clinical Medicine.2019; 8(4): 545. CrossRef

7,169 View
212 Download
16 Web of Science
14 Crossref

First
Prev
Page of 1
Next
Last

Search